Ipsen S.A. reports Q3 results; upgrades FY outlook
Source: SeekingAlpha
2025-10-22 03:09:52 ET
More on Ipsen S.A.
- Ipsen S.A. 2025 Q2 - Results - Earnings Call Presentation
- Ipsen S.A. (IPSEY) Q2 2025 Earnings Call Transcript
- Ipsen granted EU nod for Exelixis-partnered cancer drug for neuroendocrine tumors
- Historical earnings data for Ipsen S.A.
- Dividend scorecard for Ipsen S.A.
Read the full article on Seeking Alpha
For further details see:
Ipsen S.A. reports Q3 results; upgrades FY outlook
Ipsen
NASDAQ: IPSEF
IPSEF Trading
100.0% G/L:
$113.13 Last:
5 Volume:
$0 Open:
IPSEF Latest News
March 09, 2026 02:00:00 am
Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma
